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Background: Rapid advances in high throughput genomic technologies and next generation sequencing are
making medical genomic research more readily accessible and affordable, including the sequencing of patient and
control whole genomes and exomes in order to elucidate genetic factors underlying disease. Over the next five
years, the Human Heredity and Health in Africa (H3Africa) Initiative, funded by the Wellcome Trust (United
Kingdom) and the National Institutes of Health (United States of America), will contribute greatly towards
sequencing of numerous African samples for biomedical research.
Discussion: Funding agencies and journals often require submission of genomic data from research participants to
databases that allow open or controlled data access for all investigators. Access to such genotype-phenotype and
pedigree data, however, needs careful control in order to prevent identification of individuals or families. This is
particularly the case in Africa, where many researchers and their patients are inexperienced in the ethical issues
accompanying whole genome and exome research; and where an historical unidirectional flow of samples and
data out of Africa has created a sense of exploitation and distrust. In the current study, we analysed the
implications of the anticipated surge of next generation sequencing data in Africa and the subsequent data sharing
concepts on the protection of privacy of research subjects. We performed a retrospective analysis of the informed
consent process for the continent and the rest-of-the-world and examined relevant legislation, both current and
proposed. We investigated the following issues: (i) informed consent, including guidelines for performing
culturally-sensitive next generation sequencing research in Africa and availability of suitable informed consent
documents; (ii) data security and subject privacy whilst practicing data sharing; (iii) conveying the implications of
such concepts to research participants in resource limited settings.
Summary: We conclude that, in order to meet the unique requirements of performing next generation
sequencing-related research in African populations, novel approaches to the informed consent process are required.
This will help to avoid infringement of privacy of individual subjects as well as to ensure that informed consent
adheres to acceptable data protection levels with regard to use and transfer of such information.
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The rapid progress of high throughput genomic technolo-
gies and next generation sequencing (NGS) methods in re-
cent years has changed the scope of human genomic
studies. These advances have made it feasible to routinely
perform whole genome sequencing (WGS) and whole
exome sequencing (WES) studies, which together we sub-
sequently refer to using the acronym ‘WGES’. The power
of WGES research to generate vast amounts of high-
resolution data is unprecedented, and these sequencing
methods enable the capture of the full extent of genetic
variation in an individual’s genome or their entire gene-
coding region respectively. Such approaches have already
proven beneficial for the identification of the genetic causes
of several Mendelian disorders (for example, see [1-4]); and
the adoption of NGS in the research of complex disorders
is also becoming more feasible with the corresponding re-
ductions in the cost of these technologies (e.g. National
Heart Lung and Blood Institute Exome Sequencing Project)
[1]. Emerging WGES studies are therefore extremely di-
verse in nature and will play an essential role in determin-
ing the genetic aspects of human disease susceptibility, risk
of complications, modifiers of disease severity, outcomes
and response to therapy (including drug response). Further,
increasing numbers of researchers are becoming involved
in the secondary-use of genomic research. This trend has
been fuelled by funding agencies and journals frequently
requesting that genomic data and corresponding pheno-
typic information be shared with interested investigators or
made available in controlled access databases in order to
ensure that these data are used to their full potential and to
expedite the generation of robust results.
Due to the large-scale, collaborative nature of WGES
studies, ethical and legal issues are of increasing concern
and have important implications for society [2-4]. Since
genomic research is global in nature, these issues required
nuanced discussions to ensure that procedures and frame-
works that are adopted are culturally sensitive and ad-
equate for the settings in which they are conducted. This
is especially the case for resource-limited settings, such as
those found in Africa, where the implications of such re-
search remain to be fully established. Including sufficient
representation of different human populations in genom-
ics research is crucial to understanding the full range of
human genomic variation and a means to reducing dispar-
ities in genomics research and its applications. African
populations are of unique interest because, despite having
the highest levels of genetic diversity, living in a vast array
of environmental and cultural settings, as well as suffering
from a high burden of disease that could be studied using
genomics approaches, they have been underrepresented in
past research [5,6].
The underrepresentation of Africa in genomic research
has led to the launch of programmes, such as the HumanHeredity and Health in Africa (H3Africa) Initiative [7],
which are funded by the Wellcome Trust (UK) and the
National Institutes of Health (NIH, USA) with approxi-
mately $37 million of funding over five years. The first
round of H3Africa funding will support research into kid-
ney disease, diabetes, heart disease, obesity, tuberculosis
and African sleeping sickness; as well as the establishment
of biorepositories and a bioinformatics network [8]. Such
initiatives should aid in the development of skills and
infrastructure required for genomic research and, add-
itionally, due to the decreasing cost of NGS, lead to the se-
quencing of numerous African genomes and exomes.
Simultaneously, these studies raise unique sets of ethical
and legal challenges that should be considered in order to
ensure the protection of the study participants and their
communities, as well as the researchers themselves.
In this study, we analyse ethical and legal considerations
for Africa resulting from genomic studies involving
WGES, with particular emphasis on informed consent,
data sharing, return of research results and secondary/in-
cidental findings, as well as research participant privacy.
The right to privacy encompasses the right to control the
dissemination of information about one’s private life. It is
submitted that the large amount of data made publicly
available through WGES studies does pose a potential
threat to the privacy of individuals participating in such
studies, where true anonymisation cannot always be guar-
anteed. This is especially exacerbated through disclosure
of data in an online environment. This notion, and the ex-
tent to which it should be guarded against, shall be
expanded upon in this paper. Relevant South African le-
gislation is examined and benchmarked against major for-
eign jurisdictions such as the USA and the European
Union (EU) in order to determine to what extent there is
universality, or conversely divergence, on relevant aspects.
This study aims to be a starting point for researchers
involved in WGES in African populations by raising
some of the ethical and legal considerations that need to
be addressed in order to protect the interests of the
study participants as well as the researchers. We ac-
knowledge the intricate nature of these concepts and
therefore only aim to discuss some of the most pertinent
issues raised by these technologies in research settings
on the African continent. The issues that need to be
addressed before implementing WGES into clinical care
in this environment are beyond the scope of this debate.
Discussion
Ethical concerns for whole genome and whole exome
sequencing studies
Informed consent
Genomic studies involving human research subjects typ-
ically require ethical clearance from relevant institutional
review boards (IRBs) or research ethics committees
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bers of the IRBs/RECs determining whether the research
protocol will gather sufficient informed consent from
study participants to ensure that these individuals are
able to make informed decisions regarding potential
risks and benefits of voluntary participation [9]. The
consent procedure should be an on-going process, which
involves more than only an initial informed consent
document: researchers should engage prospective study
participants in frequent discussions about their re-
search, as well as give them adequate time to decide
whether they wish to participate in the proposed re-
search, ensuring that participants realise that participa-
tion is voluntary. In certain settings, consultations with
the community may also be appropriate (see the sec-
tion, ‘Challenges and opportunities in the African con-
text’, below).
NIH-funded research involving human subjects is
guided by the US Department of Health and Human
Services Policy for the Protection of Human Research
Subjects Code of Federal Regulations, 45 CFR Part 46
[10]. Of relevance to research in Africa is the fact that
the informed consent process of projects funded by the
H3Africa Initiative will be required to comply with the
so-called ‘Common Rule’ (i.e. subpart A of 45 CFR Part
46) [11]. Published in 1991, a large part of these regula-
tions were derived from concepts from the Belmont Re-
port [12,13], a report that places emphasis on: (i) respect
for persons, (ii) beneficence and (iii) justice. The ‘Com-
mon Rule’ is the basic policy for the protection of hu-
man research subjects for federally funded research in
the USA. The policy covers aspects such as general re-
quirements for informed consent and criteria for IRB
membership and oversight.
The informed consent document should contain a var-
iety of different elements presented in a concise manner
to ensure that participants can easily comprehend the
text. Elements normally included are a brief description
of the project, the goals of the research, the potential
risks and benefits of participation, return of results, op-
tions for withdrawal from research and data sharing
plans. It is imperative for the informed document to be
written in accessible language to promote research par-
ticipant autonomy and awareness of potential benefits or
harms of participation.
Data sharing
One of the key aspects of genomic research, which is
frequently adopted by these studies (including those
studies involving WGES), is the concept of data sharing
through databases to allow for the secondary use of data.
Such data sharing has been employed in the field of hu-
man genomics since the advent of genome wide associ-
ation studies (GWAS) [14]. Increasing data access hasallowed genomic datasets to be thoroughly analysed, and
has afforded research groups without data-generating
capacity the opportunity to interrogate genomic data.
The related benefits to society of these data sharing
practices have led certain public funding agencies as well
as journals to require researchers to deposit genomic
data and correlated deidentified phenotypic information
into public databases. For example, the federally-funded
NIH expects research resources generated by NIH pro-
jects to be shared with the scientific community unless
there are adequate reasons that would justify that ex-
emption (e.g. data sharing not covered in the original
consent documents, institutional policies, etc.) [15].
Examples of such databases include the Database of
Genotypes and Phenotypes (dbGaP) and the European
Genome-phenome Archive (EGA). These databases were
originally operated under open access models; this prac-
tice, however, is no longer endorsed by the NIH and
Wellcome Trust since a study by Homer et al. [16]
displayed that certain genotypic information makes it is
possible to determine whether a particular individual
participated in a GWAS [17]. Currently, these databases
are typically operated under restricted/controlled access
and data access committees oversee the dissemination of
such data.
As illustrated by Homer et al. [16], despite the ‘prac-
tical obscurity’ of genomic data, privacy and issues
pertaining to identifiability are inherent concerns when
genomic data sharing is practiced. Additionally, privacy
risks are not exclusive to the genomic research partici-
pants themselves, but extend to their families too.
Although personal identifiers are removed from genotype-
phenotype data in public databases, the risk of the inference
of individuals by data intruders still exists due to richness
of such data and increasing numbers of different types
of public databases [17-21]. Therefore dbGaP and EGA
require users requesting to gain access to individual
genotype-phenotype information to sign agreements
that state that data will not be used to attempt to iden-
tify participants and that data confidentiality will be
maintained. These are data use certification [22] and
data access agreements [23], respectively. It is, however,
impossible to guarantee absolute confidentiality to research
participants in genomic studies, and it is important
that such a caveat is included in the informed consent
document. Finally, once the data have been deposited
in these databases, withdrawal from research – an option
frequently found in informed consent documents –
becomes challenging [2].
For these reasons, the sensitive nature of genomic data
with regards to identifiability and privacy, as well as stig-
matisation and discrimination that could result from
data breaches, are major concerns in these studies, while
the physical harms of participating in such research are
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draw): unlike traditional clinical research, the major
harms of genomic research are not physical, but psycho-
social in nature [9]. These risks of data sharing need
to be carefully measured against the potential loss
of medical advancement to society through withholding
the data.
Participant identifiability
The deluge of data that are generated in WGES studies
differ dramatically from DNA microarray-based GWAS
since, theoretically, all the genetic variants that change
protein sequences in an individual are catalogued,
heightening the ethical and legal concerns encountered
in traditional genetic studies. The extensive nature of
these WGES data, as well as links to corresponding
phenotypic and familial data, increases the likelihood of
identifiability of research participants and complicates
the informed consent process [24,25]. These concerns
provide challenges for IRBs/RECs as well as investigators
wanting to conduct WGES studies, since due to the
emerging nature of WGES technologies, empirical evi-
dence and policies regarding these concepts are lacking.
Due to these concerns, the contents of the informed
consent document come under increased scrutiny in
WGES studies. This is of particular relevance to samples
that were collected before NGS era of medical genomic
research, and IRBs/RECs could conclude that partici-
pants need to re-consent to the WGES part of the study.
Although the goals of traditional genetic and genomic
studies do not differ greatly from WGES studies, there is
still some debate whether research participants need to
be specifically informed about the use of WGES in a
study, and if so, how extensive and in what language the
description of the WGES approach should be in the con-
sent document [4,26]. Practicing genomic data sharing is
also another potential issue here if the individuals were
not advised about this concept in the original informed
consent documents [27]. Further, WGES approaches are
far more prone to uncover secondary or incidental re-
search findings (i.e. those not related to the primary re-
search aims/scope of the study) and if there is to be an
option for such results to be returned to research partic-
ipants, this should be clarified in the informed consent
document [28]. This last concept will be discussed in
more detail later.
The use of broad consent has been suggested as a pos-
sible solution to allow for genomic data to be shared as
well as permitting the inclusion of DNA samples in
biorepositories [14,29]. This will come under heightened
inspection with the advent of WGES studies, since
the use of broad consent models opens concerns about
decreased research participant autonomy and may im-
pair their ability to make informed decisions [14,25].The feasibility of using narrow consent models for
biorepositories is questionable; since this would hamper
research outputs from these resources and could neces-
sitate excessive re-contact of research participants. Re-
search involving potential biorepository participants in
the US indicates that privacy is a notable concern for
these individuals and should be addressed in future in-
formed consent documents [30].
The privacy risks associated with WGES data sharing
are increased due to the scope of these data, which in-
clude information on rare alleles as well as variants of
clinical utility that will aid in re-identification of sam-
ples. Research has shown that it may be possible to use
DNA chip data from the HapMap Project [31] to predict
the potential surnames of participants from this initiative
[20] and it has recently been displayed that similar strat-
egies, using free, publically available resources, can be
employed with personal genome datasets to identify if
analysed in conjunction with other available data (e.g.
age and place of birth) [21]. Further, as the tools to ana-
lyse WGES data improve, profiling of identifiable pheno-
typic traits will become more straightforward [19,32]
and Mendelian diseases, which are frequently included
in WGES studies, are also easier to re-identify due to
their rarity and unique pedigrees that are often included
in publications.
Return of research results and secondary/incidental findings
Due to the fact that WGES technologies efficiently ana-
lyse the entire genome and exome respectively; second-
ary, incidental or unrelated findings that were not part
of the original research hypothesis may be encountered,
which places emphasis on the researchers’ duty to in-
form participants of such results. The dilemma faced by
genetic/genomic researchers in handling such findings is
not new, yet the scope of the results generated by WGES
exponentially amplifies the probability of encountering
these findings exponentially [33]. It has been suggested
that ethical obligations and legal duties for returning re-
search results may exist [28,34-38]. For example, Wolf
et al. [34] highlight the relevant ethical concepts of reci-
procity between researchers and their participants and
the welfare and autonomy of the research participants;
and legal obligations such as the development of man-
agement plans for secondary/incidental results, as well
as the implementation of these when required. The
moral duty to warn research participants of secondary/
incidental variants of interest, however, needs to bal-
anced against opposing duties such as the limits of
beneficence, excessive burdens on researchers, and the
fact that returning results may be harmful (e.g. cause
anxiety) [39].
If an option to return secondary/incidental findings
to research participants will be given in a study, it is
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returned to these individuals in order to minimise risks
and increase benefits of such a practice. Since it is not
feasible to return all WGES data that have been associ-
ated with clinical phenotypes to participants, re-
searchers must determine which type of genetic
variants should be returned to research participants.
Current thinking suggests that these variants should
have clinical relevance, have implications for health and
are medically actionable [26,33,40]. Categorical ap-
proaches such as the binning of genomic variants
according to clinical relevance during interpretation
may aid in reducing such data into manageable portions
[41]. Expert, confidential consultation sometimes may
be required to predict the relevance of particular find-
ings [42] and should be incorporated into the design of
the informed consent process [34]. During the informed
consent process, it is also important to explain to the
participants the implications of returning secondary/in-
cidental findings and then to subsequently determine
whether the research participants would opt to receive
these results, and what their expectations are in this re-
gard. Further, ensuring analytical validity through add-
itional verification steps and incorporation of genetic
counselling are important steps to include in disclosure
plans [28].
Despite these recommendations, debate exists with
regards to the practice of returning secondary/incidental
findings from WGES research and other genomic stud-
ies. Some have suggested that the return of research
results may distort the line between research and clinical
practice [9,37] and that burdensome legal liabilities for
researchers may be created [43]. Another complication
arises when attempting to determine what results are
considered clinically relevant and how substantial the
related risks need to be in order to be considered
meet the criteria for such return [36,42,44]. This is
particularly challenging with novel variants, which is
highly relevant for WGES research [4]. In this regard,
it is important to draw a distinction between GWAS
and WGES studies. GWAS-associated loci for most
diseases are often associated with small-to-moderate
risk (Odds Ratios of 1.3-1.6) and have low predictive
value for an individual. Therefore, their clinical rele-
vance and potential for being actionable are quite
limited. WGES studies on the other hand often find
coding mutations with large effect sizes, some of
which are already annotated as disease-causing (for ex-
ample in the Human Gene Mutation Database). For
instance, it is estimated that healthy individuals carry,
on average, approximately >2 robust disease-causing
mutations in their genomes [45]. This makes the issue
of secondary/incidental findings far more complex in
WGES studies.The aspects discussed above need to be considered
when designing qualified results disclosure programs
[39] and should be incorporated into future research
studies attempting to generate empirical evidence on re-
turn of secondary/incidental findings. Initiatives such as
My46 [46], which aims to gather participants’ opinions
and preferences for the return of WGES research results,
should aid in better understanding the intricacies of this
concept better. Sets of guidelines and policy statements
produced by workgroups from organisations such as the
American College of Medical Genetics and Genomics
[47] with regards to the application of NGS technologies
in clinical settings (including secondary/incidental findings)
could also provide useful information for research environ-
ments. Additionally, a preliminary study of specialists’
opinions for the management of WGES secondary/
incidental findings – ordered for clinical purposes – cited
64 genetic conditions or genes that have strong evidence
for return to patients [48]. As such lists emerge, they
could help guide research studies. In the interim, it is
important for researchers to work intimately with their
respective IRBs/RECs during processes such as the review
of WGES research protocols.
Challenges and opportunities in the African context
Cultural and genetic diversity in Africa
It is essential to perform WGES studies in Africa to en-
sure that the benefits of genomic medicine are also
eventually realised in these populations. Conducting re-
search in the culturally as well as genetically diverse
populations of Africa, however, requires unique consid-
erations to ensure that this research is performed in a
manner that is respectful to cultural differences; and
community engagement can be helpful in certain situa-
tions. Previous large-scale genomics projects involving
indigenous African populations, such as the HapMap
Project [31], aimed to document unforeseen issues and
ensure that culturally sensitive research was achieved
through consultation with community advisory groups
[49,50]. For example, certain tissues and materials may
have unique cultural significance in specific African pop-
ulations and researchers need to be aware of such facts
when collecting samples for genomic research [51,52].
It is important for advisory groups to be representative
of the socio-economic makeup of the actual communi-
ties [53], yet guidelines for conducting community en-
gagement are notably lacking [54]. The selection of the
appropriate members for such advisory groups is there-
fore a major concern [53-55], and can lead to what has
referred to as ‘pseudo-community engagement’ [53].
Despite the fact that appropriate community engage-
ment can be a complex, time-consuming process, it aids
in establishing strong collaborations between researchers
and research participants [56]. This is in contrast to so-
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sustainable research conditions and creates feelings of
distrust of research amongst the respective communities.
If performed correctly, community engagement helps
address group concerns, increases the community’s un-
derstanding of the respective research, aids in preventing
exploitation, enhance recruitment of research partici-
pants and helps maintain openness and transparency be-
tween researchers and potential study participants. Such
processes can also be used to determine how the re-
spective populations would like to be named and de-
scribed in subsequent research.
Studies are required with regards to opinions of risks
associated with identifiability caused by genomic re-
search in the African context. The risks associated with
identifiability associated with participating in genomic
research will be of increased concern when diseases/dis-
orders that have stigma associated with them in Africa
are studied (e.g. mental health [58] and HIV/Aids [59]).
Additionally, in Africa individuals frequently define
themselves with regards to a community, rather than as
a lone individual [60]. Therefore, these differences to
Western thought need to acknowledged and the poten-
tial for group harm resulting from inclusion of certain
ethnic groups needs to considered.
As mentioned above, the results of genetic/genomic
research, including WGES studies, may result in con-
cerns about discrimination and stigmatisation due to re-
search findings [61,62]. In the US, Goldenberg et al. [63]
found that the potential for genetic research to cause
group stigmatisation could influence whether individuals
decide to participate in the study, a concern especially
apparent amongst African-American respondents. De
Vries et al. [64] noted that this genomics-related concern
could be relevant for ethnic groups in Africa for which
stigmatisation and discrimination is already present. The
unfortunately long list of past and on-going ethnic con-
flict and violence in many African countries suggests
that this is a real concern. In other words, genomics
findings could be used as one more piece in highlighting
perceived differences between ethnic groups that are
used to promote such conflicts. On the other hand, it
should be noted that other distinguishing characteristics
(e.g. in skin colour, height, or lifestyle) are already being
so misused. Therefore, it is uncertain if genomics find-
ings would exacerbate such issues than what currently
exists or if, in fact, the genomic similarities between eth-
nic groups will lead to a greater appreciation of the
shared humanity of all peoples, irrespective of their eth-
nicity or outward appearance. An additional concern is
that when the findings of population genomic studies do
not correspond with cultural beliefs/social narratives,
this may also cause group harm and/or create mistrust
in the utility of genomics in such societies. The filing ofpatents and the potential commercialisation of research
findings is an additional issue for genomic research in
developing countries [53], and raises the concepts of
benefit sharing and genomic sovereignty [65]. Re-
searchers need to be prepared for this possibility when
conceptualising their research.
Availability of resources in Africa
Conducting genomic research in resource-limited set-
tings, such as those in Africa, offers a unique set of chal-
lenges. Comprehension barriers to the informed consent
process may be present due to the limited income and
literacy levels of participants as well as language differ-
ences that may be encountered [54]. For example, this is
illustrated by the fact that 30.5% of the world’s living
languages have an African origin, yet these diverse lan-
guages are spoken by only 12.2% of global population
[66]. These concerns are further amplified in WGES
studies due to the complex nature of such technologies
employed [4], and the required role of IRBs/RECs: un-
fortunately, many board members may not be adequately
trained to handle genomics-related research [36,37].
With increasing WGES in Africa over the next five
years, the already limited number of local IRBs/RECs
will be placed under an increased burden, with limited
training and funding for these committees on the con-
tinent [67-69]. Due to the collaborative nature of WGES,
ethical clearance will frequently be required from mul-
tiple IRBs/RECs, further complicating matters.
IRBs/RECs also need to determine protocols for WGES-
related secondary/incidental findings in the African con-
text. Local circumstances need to be considered, such as
the feasibility of re-contacting participants (for return of
results or re-consent) in certain studies as well as in
resource-limited settings. Even if it may not be financially
viable to undertake a time-consuming search for second-
ary/incidental variants [42], researchers may have an eth-
ical obligation to return such variants if encountered
during the primary research process [34]. This situation,
however, is also set to change as the process of genome
analysis to identify relevant variants becomes increasingly
refined and automated. Another aspect that needs to be
considered is that we do not currently know the pene-
trance range of different variants that are classified as
disease-causing, which is especially relevant for African
situations where understudied and unique genetic and en-
vironmental backgrounds are present [45].
Equally important is the verification step that is re-
quired before the disclosure of secondary/incidental
findings to research participants. Current recommenda-
tions in the US require verification through laboratories
conforming to the Federal Government’s Clinical La-
boratory Improvement Amendments (CLIA); and re-
searchers working in Africa will have to determine
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ation of findings. For example, in South Africa, the South
African National Accreditation System [70] is responsible
for International Organization for Standardization (ISO)
accreditation of clinical laboratories in the country (e.g.
ISO 15189 and ISO 17025). Where resources are limited, it
may prove necessary to perform validation in foreign la-
boratories that comply with CLIA or equivalent protocols.
Once the relevant variants have been confirmed via
verification, qualified genetic counsellors should return
these results at an appropriate level for full participant
understanding. The limited numbers of genetic counsel-
lors in Africa may hamper this process. A recent review
noted that only 26 genetic counsellors were listed on the
relevant mailing list for the Southern African Society for
Human Genetics [71,72], and even in developed coun-
tries the number of genetic counsellors is limited (e.g. in
the US there is approximately one counsellor to 135 000
individuals) [44].
In the context of resource poor countries (like many in
sub-Saharan Africa), the issue of what is ‘actionable’ be-
comes much more complex than in Western nations. As-
suming availability of WGES findings, there is limited
capacity to provide genetic counselling, trace and contact
family members, institute preventive measures (when ap-
plicable) and follow up patients and their families. There-
fore, the lack of resources and the generally poor health
care systems may limit (and thereby define) what is action-
able in WGES findings. Autonomy may also be hampered
in such situations, where it would be difficult to convey
complex concepts, such as actionable findings, to research
subjects when genomic literacy is limited. There is a lack
of empirical evidence on the attitudes towards the return
of secondary/incidental in indigenous African populations,
which should be addressed in future studies. Emerging
evidence from studies of African American attitudes to-
wards WGES suggest that these individuals are less likely
to want to receive genetic results [73].
Limitations to addressing such ethical considerations
for WGES in Africa thus include poor literacy and com-
munication resources for the informed consent process;
poor financial resources for secondary analysis, limited
resources for appropriate validation and return of second-
ary data to participants, and limited capacity for health in-
terventions based on secondary findings. Investing in
Africa by providing funding for ethics processes within
WGES research, however, will aid in capacity building on
the continent and address some of these limitations.
Implications for informed consent and data sharing
processes in Africa
Diverse populations, such as those found in Africa, re-
quire unique considerations for the informed consent
process to acquire valid consent [50]. We wished tounderstand how informed consent with African partici-
pants was undertaken for previously published African
genome studies, and requested access to templates of
informed consent documentation from a number of dif-
ferent genomic studies involving indigenous African
populations, in order to analyse key concepts that were
covered in these documents. In general, the informed
consent form templates used for the genomic studies in
Africa are not available to external researchers, except
for those used by large-scale projects of human genetic
variation (i.e. the HapMap Project [31] and the 1000 Ge-
nomes Project [74]) as well as the Malaria Genomic Epi-
demiology Network (MalariaGEN) [75]. Attempts at
accessing informed consent documentation from the
corresponding authors of studies where these templates
were not publically available proved generally unsuccess-
ful. This may have been due to institutional policies (e.g.
template consent form documentation could perhaps be
considered proprietary information).
Informed consent processes for genomic research in
African populations have previously been brought under
scrutiny [76], highlighting the need to carefully consider
these processes and ensure that the forms cover the re-
quired concepts and are written in an accessible lan-
guage. Furthermore, the processes and documentation
for informed consent should be available to all interested
parties, in the interests of transparency. The potential
linguistic barriers in Africa were mentioned previously
[77], but these may be more easily overcome if scientific
jargon is avoided while using language familiar to the
participants [53]. Local vernacular terms that have
potential derogatory connotations to participants should
be avoided, distinctions between clinical care and re-
search should be articulated and it should be emphasised
that research participation is voluntary [78]. Where pos-
sible, local field workers should understand the study ad-
equately in order to perform recruitment and should
engage in feedback to other members of the research
team [79].
Efficient methods to convey complicated concepts dur-
ing the informed process are required to minimize in-
convenience for research participants. Persons entrusted
to gather informed consent should verbally go through
the documentation in the home language of the re-
search participants, who should also be given sufficient
time to consider whether they wish to participate in the
study. Audio- or video-recorded verbal consent could
be used in certain situations where research participants
are illiterate [80].
With regards to data sharing, policies that were
established for the MalariaGEN, which conducted gen-
omic research in numerous sub-Saharan African coun-
tries, may serve as a primer for future WGES studies in
Africa, especially those involving large consortia [81].
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parts of MalariGEN are determined by an independent
data access committee, in consultation with local IRBs/
RECs, while considering the respective consent that was
obtained [82]. Finally, the network has adopted a note-
worthy approach to intellectual property issues, where
potential royalties will go to participating communities
and not the investigators where possible [75]. All ethics
documentation, including the informed consent tem-
plates, are available to the public.
In the subsequent section relevant South African legis-
lation for WGES studies will be discussed in relation to
UK and US laws, using this case study to gain a better
understanding of potential legal issues in African coun-
tries. South Africa has been chosen not only for its rela-
tive convenience (being known by the authors), but also
due to the fact that it often serves as a legislative blue-
print for other (especially Anglophone) African coun-
tries, and is therefore a pertinent point of departure for
further research and comparative analysis within the
greater African continent.
Legal issues around privacy, informed consent and data
sharing
From a legal point of view, the two most important sub-
ject rights with regard to medical research are the right
to bodily integrity and the right to privacy. The former
right pertains to the methods used in acquiring samples
for research, and legislation such as the National Health
Act 61 of 2003 of the Republic of South Africa regulates
the position. In this regard, written informed consent is
required for the removal of biological material for use in
genetic research. The latter right relates to how any data
derived from such research should be dealt with, which
is the focus of this paper.
The right to privacy has been most famously described
as the right to be left alone [83], and includes the right
to control the dissemination of information about one’s
private life. In the modern context, the right to privacy
is guaranteed either expressly, in the Constitution of the
Republic of South Africa, 1996, or the UK’s Human
Rights Act, 1998, for example, or implicitly - as is the
case in the USA, where the Supreme Court stated in
Griswold v Connecticut 381 U.S. 479 (1965) that the
right is inferred. In addition, the right to privacy can
also be protected through private civil action, either
by means of delict/tort, a breach of confidence, or
contractual remedies (see National Media v Jooste
1996 (3) SA 262 (A); R v Department of Health [2001]
Q.B. 424; Restatement (Second) of Torts, American
Law Institute, 1977).
To give effect to privacy rights, many countries have
adopted legislation not only to provide a general frame-
work, but also specifically to deal with the instancesrelating to medical research. Accordingly, we shall dis-
cuss and evaluate these legislative measures, looking at
South Africa, the UK (as both a sovereign state as well
as a member of the EU), and the USA. This is done in
order to ascertain to what extent South Africa adheres
to international standards, and to identify what steps, if
any, can be taken in order to bring it in line with them.
With regard to specific legislation dealing with medical
ethical concerns, the South African position is regulated
by the National Health Act 61 of 2003, which primarily
concerns itself with aspects relating to the right to bodily
integrity. Furthermore, Regulation 13 of the Regulations
relating to the use of Human Biological Material (2012)
provides some guiding principles in relation to the stor-
age and flow of genetic information. In this regard, insti-
tutions that keep or disclose genetic material records
and other individually identifiable or related health infor-
mation must ensure, among other things, that the infor-
mation is treated confidentially and anonymously if used
for research purposes, and that written informed con-
sent is obtained before a person’s specific information is
released to any relevant person. In the USA, the Health
Insurance Portability and Accountability Act (HIPAA) of
1996 provides regulations relating to privacy and secur-
ity of patient-client records, but does not cover de-
identified information. Additionally, the Patient Safety
and Quality Improvement Act of 2005 contains more
stringent regulations regarding patient information to in-
crease patient safety. It would seem, therefore, that
equivalent protection is granted in the USA, although
seemingly only insofar as it relates to the doctor-patient
relationship, rather than the position of genetic research
participants, and, while possible, it is unsure if the legis-
lation would be interpreted extensively enough to in-
clude them as well. Some of these concerns were also
recently raised in a US report on privacy and progress in
whole genome sequencing [84]. In the UK, no additional
specific legislation apparently exists regarding privacy in
genetic research, although case law on this issue indi-
cates that the primary concern of the law is to protect
the confider/patient’s personal privacy, which can be
safeguarded through anonymisation (see R v Department
of Health [2001] Q.B. 424; Common Services Agency v
Scottish Information Commissioner [2008] UKHL 47). It
would seem, therefore, that, in general, if anonymity can
be guaranteed, the use and transfer of databases
containing WGES research should not be overly prob-
lematic. However, in instances where individual identifi-
cation (or rather, re-identification) is possible, additional
measures would have to be implemented.
Over and above the privacy concern, an additional risk
that can potentially manifest would be that the informa-
tion obtained could be used to discriminate against a re-
search participant. In this regard, specific protection is
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formation Nondiscrimination Act (GINA) of 2008, and
indirectly in South Africa through the Employment
Equity Act 55 of 1998 and the Promotion of Equality
and Prevention of Unfair Discrimination Act 4 of 2000.
The UK does not, however, provide legal protection in
this regard, and, therefore, confidentiality and the pro-
tection of personal information become critical issues
[85]. Accordingly, the general legislative framework sur-
rounding this aspect will be evaluated.
It is submitted that the UK’s lack of directly pertinent
legislation (as shown above) should not be a concern,
due to the broad protection granted through the Data
Protection Act, 1998 (which is the localised implementa-
tion of EC Directive 95/46, the so-called Data Protection
Directive). The Act seeks to protect the privacy of any
information relating to a living individual who can be
identified from the data itself or from the data and other
information, which is in the possession of the controller
of such data. In terms of Schedule 1 to the Act, certain
data protection principles (which are universally applic-
able in the EU) must be adhered to, including that data
must be processed fairly and lawfully. Accordingly, data
should be processed subject to the purposes for and the
conditions under which it was acquired, while adhering
to all relevant legal principles (be they found in legisla-
tion, conventions, or otherwise), and also bearing in
mind the nature of the data itself. With regard to the lat-
ter aspect, a distinction is drawn between merely per-
sonal data and sensitive data. Sensitive data, in terms of
Schedule 3, includes information relating to the race or
ethnic origin of a person, or their physical or mental
health. In terms of the Act, fair and lawful processing of
such data entails that the data subject give explicit con-
sent unless, among other things, the information is ne-
cessary to protect the vital interests of data subject or
another person, deliberately made public by the data
subject, or is used by a health professional and is neces-
sary for medical purposes. In this regard, it is submitted
that WGES research could be seen to be sensitive data
that would require explicit consent. This notwithstand-
ing, it must be noted (as shown above) that UK courts
are of the opinion that sufficiently anonymised data
would not be problematic.
In general, data protection in South Africa is currently
regulated by Chapter VIII of the Electronic Communica-
tions and Transactions Act 25 of 2002, which only deals
with information obtained through electronic transac-
tions, and which, therefore, would in all likelihood not
apply to most instances of WGES research. Additionally,
the specific provisions of the Act have elicited other
criticism [see Van Der Merwe et al. [86]] due to the fact
that the data protection principles do not adhere to ac-
ceptable international standards (for instance, no specialtreatment is afforded for sensitive data) and are volun-
tary in nature. To address these shortcomings, new le-
gislation has been proposed in the form of the
Protection of Personal Information Bill (B9-2009), which
provides for greater security, openness and accountabil-
ity, and also creates a distinction between standard and
‘special personal’ information which would include infor-
mation relating to WGES research, and would require
explicit consent for purposes of processing. Accordingly,
the Bill, if enacted, will bring South African data protec-
tion laws in line with EU standards, and also serve to
strengthen the current framework for privacy in WGES
research in South Africa.
In contrast to the stringent regulation found in the
European Union, and the subsequent South African at-
tempts to keep in step with these requirements, the USA
has no specific protection regarding data privacy of indi-
viduals over and above what has already been stated, ex-
cept for incidental regulation [87]. The fact that there is
no international harmony in this regard is problematic,
as both the UK Data Protection Act and the EU Data
Protection Directive provide that no transfers of data to
outside the European Economic Area may be made un-
less adequate protection is guaranteed. Accordingly, if
the stated principles are not adhered to, this could con-
stitute a barrier to both transnational research and ac-
cess to research information.
As a compromise in the above situation, an exception
exists in both the Act and Directive to allow transfers to
third countries if, among others, a data subject gives un-
ambiguous consent to a transfer – which consent must
be freely given, specific and informed - or the transfer is
on terms approved or authorised as ensuring adequate
safeguards. In this regard the European Commission has
developed prescribed standard contract terms for data
transfer agreements (Commission Decision 2010/87/
EU), as well as a method whereby a multinational cor-
poration can develop binding corporate rules that, sub-
ject to approval through EU cooperation procedures,
would ensure acceptability of a transfer (for more on
this, see [88]). Finally, the USA and EU have also entered
into a so-called ‘Safe Harbour’ agreement (Commission
Decision 2000/520/EC), which encompasses a set of vol-
untary, self-regulatory principles in order to assist in fa-
cilitating data transfer.
It would seem that the privacy concerns relating to
WGES research are not overly problematic in most
countries, as long as the anonymity thereof can be guar-
anteed. Forgó et al. [89] point out that this is, however,
not so simple, because it is necessary to keep an identifi-
able link between a donor and his genetic data to be able
to give feedback on relevant findings connected to the
donor’s genetic data, and also when one takes into ac-
count the uniqueness of genetic data. As a result, true
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search. Lowrance and Collins [19], identify methods of
mitigating this, such as through limited release of gen-
ome segments, but also indicate how this may pose its
own problems for research. Thus, it would seem that the
most prudent route is still to obtain express written con-
sent from research participants. This process does not
come without its problems, as express consent is re-
quired to be freely given, fully informed, and, with refer-
ence to processing and transfer of data, must be specific
in nature. This means that the use of informed consent
forms that are overly broad or vague may end up creat-
ing instances where researchers believe themselves to be
operating lawfully, when technically they are not. This is
further exacerbated, both legally and ethically, in the Af-
rican context, where often research is conducted using
participants who may not be literate or fully compre-
hend the nature and extent of the consent which they
purport to give.
Recommendations for future genomic studies in Africa
Future WGES studies in African populations need to
consider the points highlighted above in order to per-
form appropriate research. Although not all-inclusive,
this would be aided by the development of local WGES-
related policies (including the promotion of sharing in-
formed consent documentation), as well as the invest-
ment in relevant training and the development of
educational aids. A variety of useful online resources
for ethical and legal considerations for WGES studies in
African populations can be found in Table 1.
Development of local WGES-related policies
The development of local policies and legislation that
are relevant to WGES research (e.g. informed consent,
data sharing, and the return of results) will be essential
for performing successful genomics research in Africa. It
is recommended, as far as possible, that standardised
methods to obtain informed consent from researchTable 1 Useful online ELSI resources, especially relevant for p
Resource
H3Africa High-Level Principles on Ethics, Governance and Resourc
Informed Consent: Ethical Considerations for Investigators Proposing to Col
H3Africa Program
NIH National Human Genome Research Institute: Informed Consent for G
NIH Office of Extramural Research: Protecting Human Research Partic
About the 1000 Genomes Project (Informed Consent Temp
Training and Resources in Research Ethics Evaluation
MalariaGEN: Ethics and Governance
Southern African Society for Human Genetics: Documents andparticipants should be developed in order to ensure that
a generally applicable and recognisable procedure is
established. It is advisable not only to have these forms
drafted in the lingua franca of research participants, but
also in language which is clear, succinct and easy to
understand. Even when not dealing with illiterate partici-
pants, it is generally best practice to explain the nature
and extent of the informed consent document in order
to fully ensure observance with both the letter and the
substance of the laws surrounding research and data
protection. In the instance where one does deal with
illiterate participants, it is technically possible to obtain
written consent through the use of a thumbprint or
other identifying mark if one is able to provide proof
that the ‘signed’ document has been adequately
explained to the participant. In this regard, additional in-
formation providing means, such as video recordings,
would be advised.
Given that there is a movement towards greater and
more open access to WGES research and findings, it is
in the best interests of all involved to share novel ways
and best practices in order to develop a universally
applicable standard in this regard. This is particularly
relevant for templates of the informed consent docu-
mentation that have been employed in WGES studies in
African populations that have successfully been through
the IRBs/RECs review process. It has been suggested
that that this could be achieved through dedicated public
databases for such templates and/or the inclusion in
supplementary material [4]. Presently, the lack of trans-
parency in informed consent documentation at the levels
of individual researchers and universities, and that many
journals do not appear to currently have policies that
promote the availability of informed consent templates
and standard operating procedures, may hamper re-
searchers in resource-limited settings designing robust
WGES informed consent documents. Most journals that
publish genomic research insist on studies that are
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formed consent process to be publicly available on publi-
cation of the study. Journals should therefore encourage
this practice in a similar manner that it has been sup-
ported for genomic genotype-phenotype and gene ex-
pression datasets.
The sharing of this documentation should not, how-
ever, be an attempt to create ‘one-size-fits-all’ or ‘boiler-
plate’ informed consent documents, since this would not
be feasible for diverse African situations; but rather as
another resource for researchers to aid in the design of
appropriate WGES research. Relevant, rapid assessment
processes in rural communities prior to the commence-
ment of genomic studies in particular communities can
used to subsequently tailor the consent process in a cul-
turally appropriate manner [78,90]. Such surveys could
aid future African WGES studies in the conceptualisa-
tion stages of genomic research.
The development of WGES data sharing and data re-
lease policies will be essential for future genomics research
on the African continent and should be performed in close
consultation with stakeholders. African funding agencies,
such as the South African National Research Foundation
and the South African Medical Research Council, do not
currently require genomic data to be made publically
available. Clear WGES data sharing policies that are rele-
vant for local research should therefore be drafted by such
agencies in the future, making sure to adhere to inter-
nationally accepted standards.
Data security is of paramount importance for WGES
studies to prevent surreptitious use of data and it is
therefore essential that such data be protected in re-
searchers’ personal as well as public databases. High
standards of data protection should therefore be com-
monplace for genomic studies, including those involving
WGES. Further, databases of biorepositories should also
have adequate infrastructure to prevent data sensitive in-
formation from being leaked as well as data intrusion.
The use of material transfer agreements will help prevent
samples being used for purposes not originally agreed
upon and therefore aid in avoiding inappropriate research
when genetic samples are transferred between research
groups, especially when the genomic analyses of African
samples are being performed abroad [53,64,91].
Finally, IRBs/RECs need to develop qualified results
disclosure policies as well as criteria that indicate what
type of secondary/incidental research findings, if any,
need to be returned to research participants. The kind of
relationship that exists between the researchers and the
research participants could influence this [35].
Training and educational materials
Providing infrastructure for various levels of training in
the relevant concepts of the applications of NGStechnologies in human research will be important on the
continent of Africa, especially since there is a need to
improve genetic literacy in sub-Saharan Africa [92].
Workshops for training members of IRBs/RECs as well
as interested researchers will aid in ensuring informed
ethical review processes for WGES studies. Public lec-
tures/information sessions could be used to educate the
community and gauge the public perception of WGES
studies. Internationally, the ethical and legal concepts
raised by WGES studies in humans are gaining attention
[84,93]. Recommendations from the recent October
2012 US Presidential Commission for the Study of Bio-
ethical Issues Report, “Privacy and Progress in Whole
Genome Sequencing” [84], should be analysed and used
to aid in drafting recommendations for African situa-
tions. Low educational levels of research participants
with regards to genetic/genomic concepts may require
the development of unique educational materials to be
used during the informed consent process. Interactive
explanations and the use of novel technologies to ex-
plain complicated concepts to research participants will
be integral in this regard. For example, the integration of
emerging software applications (i.e. apps), similar to the
Illumina MyGenome iPad app [94], could be used during
the recruitment stage of WGES studies.
An encouraging sign for future WGES studies in
Africa is the investment in an Ethical, Legal, and Societal
Issues (ELSI) Research Program by the H3Africa Initia-
tive, which will make almost $2 million in funding avail-
able, over a period of three years [95]. The Southern
African Human Genome Programme, which will be in-
volved in the sequencing of African genomes and has
received provisional funding from the South African
Department of Science and Technology, also aims to
highlight relevant ELSI topics brought up by such re-
search [96]. Finally, meetings such as the Ethics and
Genomics Research in Africa (EAGER-AFRICA) Con-
ference [97] will positively contribute to the field by
bringing researchers from across Africa and the rest
of the world together and facilitate networking and
collaboration.
Ethical, legal and societal issues (ELSI)-related research
needs in Africa
While a number of ELSI-related research studies have
now been conducted in Africa [for example, see Marshall
et al. [77], MalariaGEN [81], Tekola et al. [62,78], Nyika
[69], Marsh et al. [79]], more studies are urgently needed.
Such ELSI research could include:
– Issues of informed consent, data sharing,
identifiability and disclosure of secondary/incidental
findings in WGES studies in contrast to GWAS or
candidate gene studies in Africa.
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relation to ethnicity and identity in sub-Saharan
Africa.
– Ethical and legal aspects of biorepositories and long-
term storage/distribution of biological material for
genomic studies.
– Analysis of how IRBs/RECs in African countries and
institutions currently review WGES studies.
– The relevance of local African legislation and
governmental policies in the context of WGES
studies in African populations.
These and some other issues are highlighted in the
2012/13 H3Africa call for applications for ELSI research
programs (mentioned in the previous section). A sum-
mary of various ELSI issues faced by WGES in Africa
raised in this study as well as potential recommenda-
tions to help address some of the aspects can be found
in Table 2.
Summary
It is essential to perform WGES studies in African popu-
lations to ensure that the benefits of genomic medicine
are available to all global populations. This is especially




Limited availability of informed consent documen
templates for genomic studies in African popula
Cultural and ethnic diversity in Africa
Language differences
Limited data on local views on genomic data sh
and related concepts (e.g. privacy and stigmatisa
Disseminating
secondary findings
Lack of local policies and guidelines
Insufficient genetic counsellors and bioinformat
Limited understanding of the penetrance of genetic




Current legislation is not drawn up with medical
research in mind
Numerous African countries with different legisl
Limited resources Poor education/literacy levels
Limited numbers of IRBs/RECs and many membe
not familiar with genomic principles
Ability to perform the equivalent of CLIA-validati
local laboratories may be lackingpotential pitfalls of DNA microarray-based GWAS in
these individuals (e.g. low marker and linkage disequilib-
rium coverage) [98]. Sustainable WGES research re-
quires strong multi-disciplinary collaborations, and in
Africa will require the principle of reciprocity to be em-
braced by researchers and the avoidance of the one-
sided South to North shipment of samples that has been
frequently encountered in the past. One of the benefits
of the H3Africa Initiative is that collaborations will be
strengthened not only between Africa and the rest of the
world, but between African countries themselves. Re-
searchers should act as stewards for research partici-
pants and transparent research should be promoted to
ensure researcher-participant trust.
Key WGES study stakeholders, such as researchers,
participants and the public, need to be consulted if soci-
ety is going to readily adopt precision medicine in the
future. Empirical research and conceptual analyses in
African populations regarding identifiability risks for
participants in WGES studies need to be performed as
well as participants’ preferences with respects to these
concepts are required. Currently, research participants
should give express consent for data sharing and in the
future, studies of attitudes towards the concept of privacy




Journals and researchers should promote the public
availability of these documents
Community engagement, rapid assessment processes and
local field workers




Generate empirical data on these concepts and opinions
through relevant research
Perform studies on African research participants’ attitudes
towards return of WGES results. Encourage IRBs/RECS to
develop such documentation




Investment in African WGES medical research and
related infrastructure
WGES The development of local legislation that is relevant
for WGES research and in line with international
best practices
ation Conduct jurisprudence studies that analyse relevant
legislation in understudied African countries
Development of unique, accessible educational materials
rs are Perform training workshops and ensure that funding is
allocated to these groups
on in Analyse local laboratory standards and perform validation
in foreign laboratories if necessary
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cial stigmatisation and individual privacy) and the benefits
(e.g. advancement of research and clinical applications) of
WGES research will ensure a sustainable future for these
studies. To conclude, local ethical and legal frameworks
that are appropriate for the WGES era of research are ur-
gently required in Africa. However, until these guidelines
are in place, IRBs/RECs will have to analyse the eligibility
of different studies on a case-by-case basis.
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